119 related articles for article (PubMed ID: 8280597)
21. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
22. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
[TBL] [Abstract][Full Text] [Related]
23. Expression of DNA topoisomerases in chronic proliferative kidney disease.
Ivanova LV; Rudolph P; Kellner U; Jürgensen A; Tareeva IE; Alm P; Proppe D
Kidney Int; 2000 Oct; 58(4):1603-12. PubMed ID: 11012894
[TBL] [Abstract][Full Text] [Related]
24. DNA-topoisomerase I and II: biologic features and their role in drug resistance.
Russo D; Marie JP; Delmer A; Zhou D; Suberville AM; Baccarani M; Zittoun R
Haematologica; 1993; 78(4):201-7. PubMed ID: 8294050
[No Abstract] [Full Text] [Related]
25. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Beck WT; Danks MK
Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
[TBL] [Abstract][Full Text] [Related]
26. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
[TBL] [Abstract][Full Text] [Related]
27. A possible role for topoisomerase II in cell death and N-phosphonoacetyl-L-aspartate-resistance frequency and its enhancement by 1-beta-D-arabinofuranosyl cytosine and 5-fluoro-2'-deoxyuridine.
Goz B; Bastow KF
Mutat Res; 1997 Aug; 384(2):89-106. PubMed ID: 9298118
[TBL] [Abstract][Full Text] [Related]
28. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
[TBL] [Abstract][Full Text] [Related]
29. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
Tan KB; Mattern MR; Eng WK; McCabe FL; Johnson RK
J Natl Cancer Inst; 1989 Nov; 81(22):1732-5. PubMed ID: 2553992
[TBL] [Abstract][Full Text] [Related]
30. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
[TBL] [Abstract][Full Text] [Related]
31. Bacteriophage T4, a model system for understanding the mechanism of type II topoisomerase inhibitors.
Kreuzer KN
Biochim Biophys Acta; 1998 Oct; 1400(1-3):339-47. PubMed ID: 9748648
[TBL] [Abstract][Full Text] [Related]
32. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
33. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
34. Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair.
Stevnsner T; Bohr VA
Carcinogenesis; 1993 Sep; 14(9):1841-50. PubMed ID: 8403208
[TBL] [Abstract][Full Text] [Related]
35. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
36. DNA topoisomerase II mutations and resistance to anti-tumor drugs.
Vassetzky YS; Alghisi GC; Gasser SM
Bioessays; 1995 Sep; 17(9):767-74. PubMed ID: 8763829
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional regulation of topoisomerase II alpha at confluence and pharmacological modulation of expression by bis-benzimidazole drugs.
Tolner B; Hartley JA; Hochhauser D
Mol Pharmacol; 2001 Apr; 59(4):699-706. PubMed ID: 11259613
[TBL] [Abstract][Full Text] [Related]
38. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.
Ritke MK; Yalowich JC
Biochem Pharmacol; 1993 Dec; 46(11):2007-20. PubMed ID: 8267650
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines.
Mo YY; Beck WT
Oncol Res; 1997; 9(4):193-204. PubMed ID: 9268990
[TBL] [Abstract][Full Text] [Related]
40. Topoisomerases II alpha and beta as therapy targets in breast cancer.
Isaacs RJ; Davies SL; Wells NJ; Harris AL
Anticancer Drugs; 1995 Apr; 6(2):195-211. PubMed ID: 7795268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
